Subtype
Human Papillomavirus-Related Malignant Neoplasm
CI-CAN-00002898Explore in graph →
70 active trials
- NCIt
- C27718
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002898Explore in graph →
Clinical trials
168 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (15)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | recruiting | Phase 2 | 455 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05600842 | De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | recruiting | — | 111 | University of California, IrvineOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04927650 |
| Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening |
| active not recruiting |
| — |
| 2,556 |
| University of California, San FranciscoOTHER |
| 1 |
| May 4, 2026 |
| clinicaltrials |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05714657 | Shortened Course Adjuvant Radiotherapy Following TORS | active not recruiting | Phase 2 | 104 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | active not recruiting | Phase 1 / Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 24 | Precigen, IncINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03621696 | Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"(MINT) | completed | Phase 2 | 63 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02379520 | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA(HESTIA) | completed | Phase 1 | 32 | Baylor College of MedicineOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06508138 | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection(J21112LINKED) | enrolling by invitation | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04857528 | Detecting HPV DNA in Anal and Cervical Cancers | recruiting | — | 20 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca(MINIMA) | recruiting | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03978689 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 80 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05524025 | The SPOT-HPV Study | completed | — | 360 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05262010 | A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | recruiting | Phase 3 | 13,500 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04474821 | HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults | completed | Phase 4 | 100 | Mayo ClinicOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06756269 | To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | recruiting | Phase 2 | 330 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04580446 | HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer | completed | Phase 1 | 24 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06730412 | ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)(Clear-HPVca) | completed | — | 103 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05247853 | HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV | completed | — | 3,127 | Montefiore Medical CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT04979000 | HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors | completed | — | 49 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04180215 | A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers | completed | Phase 1 / Phase 2 | 198 | Hookipa Biotech GmbHINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03728881 | Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial(PRIMAVERA) | completed | Phase 3 | 1,240 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07087145 | Feasibility of HPV Testing With Mail-delivered Sample Collection Kits | recruiting | — | 135 | University of California, San FranciscoOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06574087 | Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases. | recruiting | N/A | 248 | PCK Marine Hospital in GdyniaOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05996783 | Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial(ScreenUrSelf) | active not recruiting | N/A | 48,000 | Universiteit AntwerpenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04142398 | Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men | withdrawn | — | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 6, 2025 | clinicaltrials |
| NCT03061435 | Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.(Vulvar-AIN) | recruiting | N/A | 110 | Dr. Danielle VicusOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06052033 | Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection | recruiting | N/A | 40 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT03944915 | De-Escalation Therapy for Human Papillomavirus Negative Disease(DEPEND) | completed | Phase 2 | 35 | University of ChicagoOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03107182 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer(OPTIMA-II) | completed | Phase 2 | 72 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03749707 | HPV in Sentinel Lymph Nodes of Cervical Cancer Patients | completed | N/A | 127 | University of AarhusOTHER | 1 | Apr 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2026source: clinicaltrials